What is Fractyl Health's operating income?

Fractyl Health's total operating income in 2025 was -$96.82 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $96.82 million

Fractyl Health (GUTS) Financials

$0.79 +0.03 (+3.86%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$0.80 +0.01 (+0.69%)

As of 07/9/2026 07:47 PM Eastern

Compare

Annual Income Statements for Fractyl Health

This table shows Fractyl Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-94	-70	-141
Consolidated Net Income / (Loss)	-77	-69	-141
Net Income / (Loss) Continuing Operations	-77	-69	-141
Total Pre-Tax Income	-77	-69	-141
Total Operating Income	-51	-94	-97
Total Gross Profit	0.04	0.04	0.00
Total Revenue	0.12	0.09	0.00
Operating Revenue	0.12	0.09	0.00
Total Cost of Revenue	0.08	0.05	0.00
Operating Cost of Revenue	0.08	0.05	0.00
Total Operating Expenses	51	94	97
Selling, General & Admin Expense	13	23	22
Research & Development Expense	38	70	75
Total Other Income / (Expense), net	-26	25	-44
Interest & Investment Income	1.26	4.15	1.54
Other Income / (Expense), net	-28	21	-46
Preferred Stock Dividends Declared	17	1.74	0.00
Basic Earnings per Share	($45.29)	($1.62)	($1.86)
Weighted Average Basic Shares Outstanding	2.08M	43.54M	75.82M
Diluted Earnings per Share	($45.29)	($1.62)	($1.86)
Weighted Average Diluted Shares Outstanding	2.08M	43.54M	75.82M
Weighted Average Basic & Diluted Shares Outstanding	-	48.92M	158.65M

This table shows Fractyl Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-20	-24	-5.06	-17	-23	-25	-24	-28	-46	-44	9.22
Consolidated Net Income / (Loss)	-16	-19	-3.32	-17	-23	-25	-24	-28	-46	-44	9.22
Net Income / (Loss) Continuing Operations	-16	-19	-3.32	-17	-23	-25	-24	-28	-46	-44	9.22
Total Pre-Tax Income	-16	-19	-3.32	-17	-23	-25	-24	-28	-46	-44	9.22
Total Operating Income	-14	-13	-22	-23	-24	-25	-25	-26	-23	-23	-21
Total Gross Profit	0.01	0.01	0.01	0.02	0.01	0.00	0.00	0.00	0.00	-	0.00
Total Revenue	0.04	0.01	0.03	0.04	0.01	0.00	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.03	0.00	0.02	0.02	0.01	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	14	13	22	23	24	25	25	26	23	23	21
Selling, General & Admin Expense	4.50	2.82	7.13	6.24	4.80	4.93	5.32	4.93	5.24	6.79	5.22
Research & Development Expense	9.38	10	14	17	19	20	19	21	17	16	16
Total Other Income / (Expense), net	-1.87	-6.20	18	5.76	0.62	0.24	1.02	-1.81	-23	-20	30
Interest & Investment Income	0.23	0.46	1.10	1.38	0.95	0.73	0.50	0.23	0.17	0.65	0.59
Other Income / (Expense), net	-2.10	-6.66	17	4.38	-0.33	-0.49	0.52	-2.04	-23	-21	29
Basic Earnings per Share	($9.61)	($11.19)	($0.17)	($0.36)	($0.48)	($0.61)	($0.49)	($0.57)	($0.71)	($0.09)	$0.06
Weighted Average Basic Shares Outstanding	2.09M	2.08M	29.74M	47.90M	47.97M	43.54M	48.87M	49.04M	64.65M	75.82M	158.49M
Diluted Earnings per Share	($9.61)	($11.19)	($0.17)	($0.36)	($0.48)	($0.61)	($0.49)	($0.57)	($0.71)	($0.09)	$0.06
Weighted Average Diluted Shares Outstanding	2.09M	2.08M	29.74M	47.90M	47.97M	43.54M	48.87M	49.04M	64.65M	75.82M	158.49M
Weighted Average Basic & Diluted Shares Outstanding	-	0.00	47.90M	47.93M	48.10M	48.92M	48.98M	50.29M	137.04M	158.65M	158.65M

This table details how cash moves in and out of Fractyl Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-16	34	14
Net Cash From Operating Activities	-43	-66	-90
Net Cash From Continuing Operating Activities	-43	-66	-90
Net Income / (Loss) Continuing Operations	-77	-69	-141
Consolidated Net Income / (Loss)	-77	-69	-141
Depreciation Expense	0.29	0.68	1.13
Non-Cash Adjustments To Reconcile Net Income	33	-7.10	50
Changes in Operating Assets and Liabilities, net	0.99	9.59	-0.40
Net Cash From Investing Activities	-0.36	-1.77	-0.56
Net Cash From Continuing Investing Activities	-0.36	-1.77	-0.56
Purchase of Property, Plant & Equipment	-0.36	-1.77	-0.56
Net Cash From Financing Activities	27	101	105
Net Cash From Continuing Financing Activities	27	101	105
Repayment of Debt	-0.48	-0.19	-0.46
Repurchase of Common Equity	-0.56	-2.85	0.00
Issuance of Common Equity	0.00	104	85
Other Financing Activities, net	0.05	0.57	20
Cash Interest Paid	0.76	3.13	4.30

This table details how cash moves in and out of Fractyl Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	17	-11	88	-19	-18	-17	-25	-20	55	3.88	-18
Net Cash From Operating Activities	-11	-11	-12	-19	-18	-17	-25	-21	-23	-21	-22
Net Cash From Continuing Operating Activities	-11	-11	-12	-19	-18	-17	-25	-21	-23	-21	-22
Net Income / (Loss) Continuing Operations	-16	-19	-3.32	-17	-23	-25	-24	-28	-46	-44	9.22
Consolidated Net Income / (Loss)	-16	-19	-3.32	-17	-23	-25	-24	-28	-46	-44	9.22
Depreciation Expense	0.08	0.04	0.05	0.19	0.21	0.22	0.29	0.27	0.29	0.28	0.28
Non-Cash Adjustments To Reconcile Net Income	4.97	7.35	-12	-0.74	2.78	2.73	0.27	3.20	24	22	-27
Changes in Operating Assets and Liabilities, net	-0.32	1.19	3.42	-0.96	2.15	4.98	-1.90	3.22	-1.50	-0.22	-4.49
Net Cash From Investing Activities	-0.15	-0.14	-1.06	-0.26	-0.21	-0.23	-0.45	-0.10	-0.01	-0.00	0.00
Net Cash From Continuing Investing Activities	-0.15	-0.14	-1.06	-0.26	-0.21	-0.23	-0.45	-0.10	-0.01	-0.00	0.00
Purchase of Property, Plant & Equipment	-0.15	-0.14	-1.06	-0.26	-0.21	-0.23	-0.45	-0.10	-0.01	-0.00	0.00
Net Cash From Financing Activities	28	-0.56	101	-0.01	0.16	0.07	0.17	1.48	78	25	4.11
Net Cash From Continuing Financing Activities	28	-0.56	101	-0.01	0.16	0.07	0.17	1.48	78	25	4.11
Repayment of Debt	-0.40	-0.08	-0.00	-0.02	-0.06	-0.11	-0.11	0.11	-0.34	-0.12	-0.12
Issuance of Common Equity	-	-	104	-	-	-	0.00	1.59	78	5.58	0.17
Other Financing Activities, net	-0.00	0.02	0.16	0.02	0.22	0.17	0.28	-0.22	0.22	20	4.06
Cash Interest Paid	0.15	0.61	0.62	0.63	0.74	1.14	1.09	1.04	1.08	1.08	1.06

This table presents Fractyl Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Total Assets	76	108	121
Total Current Assets	36	72	88
Cash & Equivalents	33	67	82
Restricted Cash	0.32	0.00	0.00
Accounts Receivable	0.02	0.00	0.00
Inventories, net	0.07	0.07	0.00
Prepaid Expenses	2.03	4.23	6.04
Plant, Property, & Equipment, net	0.49	2.98	2.41
Total Noncurrent Assets	40	33	31
Other Noncurrent Operating Assets	40	33	31
Total Liabilities & Shareholders' Equity	76	108	121
Total Liabilities	114	80	112
Total Current Liabilities	11	20	18
Accounts Payable	7.88	15	13
Other Current Liabilities	3.30	4.96	5.10
Total Noncurrent Liabilities	103	60	94
Long-Term Debt	55	30	31
Other Noncurrent Operating Liabilities	48	30	63
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-325	28	9.46
Total Preferred & Common Equity	-325	28	9.46
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-325	28	9.46
Common Stock	22	444	566
Retained Earnings	-347	-415	-556

This table presents Fractyl Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	164	146	127	83	62	114	99
Total Current Assets	124	107	88	47	27	80	66
Cash & Equivalents	121	102	85	42	22	78	63
Restricted Cash	0.32	0.32	0.00	0.00	0.00	0.00	0.00
Accounts Receivable	0.02	0.02	0.00	0.00	0.00	0.00	0.00
Inventories, net	0.07	0.06	0.07	0.00	0.00	0.00	0.00
Prepaid Expenses	2.63	3.72	2.91	4.94	4.40	2.05	2.75
Plant, Property, & Equipment, net	1.90	3.17	3.00	3.14	2.97	2.68	2.13
Total Noncurrent Assets	37	37	36	33	32	32	31
Other Noncurrent Operating Assets	37	37	36	33	32	32	31
Total Liabilities & Shareholders' Equity	164	146	127	83	62	114	99
Total Liabilities	79	76	77	77	80	117	78
Total Current Liabilities	13	14	16	19	22	19	15
Accounts Payable	9.68	9.40	11	14	17	14	10
Other Current Liabilities	3.59	4.88	4.92	4.99	5.03	5.07	5.14
Total Noncurrent Liabilities	66	61	61	57	58	99	63
Long-Term Debt	29	28	30	29	30	31	30
Other Noncurrent Operating Liabilities	37	33	31	28	28	68	32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	84	71	50	6.38	-18	-3.18	21
Total Preferred & Common Equity	84	71	50	6.38	-18	-3.18	21
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	84	71	50	6.38	-18	-3.18	21
Common Stock	434	438	441	445	449	509	568
Retained Earnings	-350	-367	-390	-439	-467	-513	-547

This table displays calculated financial ratios and metrics derived from Fractyl Health's official financial filings.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	48,098,944.00	137,044,440.00
DEI Adjusted Shares Outstanding	0.00	48,098,944.00	137,044,440.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-1.46	-1.03
Growth Metrics	-	-	-
Revenue Growth	0.00%	-22.50%	-100.00%
EBITDA Growth	0.00%	7.56%	-95.90%
EBIT Growth	0.00%	7.03%	-95.63%
NOPAT Growth	0.00%	-83.99%	-3.51%
Net Income Growth	0.00%	10.89%	-105.19%
EPS Growth	0.00%	96.42%	-14.81%
Operating Cash Flow Growth	0.00%	-53.00%	-37.86%
Free Cash Flow Firm Growth	0.00%	0.00%	51.64%
Invested Capital Growth	0.00%	44.87%	-367.40%
Revenue Q/Q Growth	0.00%	-4.12%	-100.00%
EBITDA Q/Q Growth	0.00%	-8.85%	-15.17%
EBIT Q/Q Growth	0.00%	-9.06%	-15.08%
NOPAT Q/Q Growth	0.00%	-15.04%	1.95%
Net Income Q/Q Growth	0.00%	-9.20%	-15.35%
EPS Q/Q Growth	0.00%	86.72%	21.85%
Operating Cash Flow Q/Q Growth	0.00%	-10.89%	-5.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-52.31%
Invested Capital Q/Q Growth	0.00%	-120.57%	17.12%
Profitability Metrics	-	-	-
Gross Margin	35.83%	46.24%	0.00%
EBITDA Margin	-65,054.17%	-77,594.62%	0.00%
Operating Margin	-42,363.33%	-100,570.97%	0.00%
EBIT Margin	-65,292.50%	-78,322.58%	0.00%
Profit (Net Income) Margin	-64,242.50%	-73,864.52%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	98.39%	94.31%	98.92%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	204.31%	1,476.02%	-744.17%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-102.81%	-79.05%	0.00%
Return on Assets (ROA)	-101.15%	-74.55%	0.00%
Return on Common Equity (ROCE)	1,760.15%	47,039.52%	-744.17%
Return on Equity Simple (ROE_SIMPLE)	23.72%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-36	-65	-68
NOPAT Margin	-29,654.33%	-70,399.68%	0.00%
Net Nonoperating Expense Percent (NNEP)	191.91%	-41.12%	-165.84%
Return On Investment Capital (ROIC_SIMPLE)	13.18%	-111.75%	-169.24%
Cost of Revenue to Revenue	64.17%	53.76%	0.00%
SG&A Expenses to Revenue	10,700.83%	24,841.94%	0.00%
R&D to Revenue	31,698.33%	75,775.27%	0.00%
Operating Expenses to Revenue	42,399.17%	100,617.20%	0.00%
Earnings before Interest and Taxes (EBIT)	-78	-73	-142
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-78	-72	-141
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	3.49	31.88
Price to Tangible Book Value (P/TBV)	0.00	3.49	31.88
Price to Revenue (P/Rev)	916.67	1,065.42	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3,491.32	664.32	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-1.46	1.06	3.23
Long-Term Debt to Equity	-1.46	1.06	3.23
Financial Leverage	-0.57	1.68	-2.33
Leverage Ratio	-2.02	-19.80	6.06
Compound Leverage Factor	-1.99	-18.67	5.99
Debt to Total Capital	316.60%	51.48%	76.38%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	316.60%	51.48%	76.38%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1,649.43%	0.00%	0.00%
Common Equity to Total Capital	-1,866.03%	48.52%	23.62%
Debt to EBITDA	-0.71	-0.42	-0.22
Net Debt to EBITDA	-0.28	0.52	0.36
Long-Term Debt to EBITDA	-0.71	-0.42	-0.22
Debt to NOPAT	-1.55	-0.46	-0.45
Net Debt to NOPAT	-0.61	0.57	0.75
Long-Term Debt to NOPAT	-1.55	-0.46	-0.45
Altman Z-Score	-8.79	-6.28	-7.99
Noncontrolling Interest Sharing Ratio	-761.50%	-3,086.91%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.19	3.63	4.78
Quick Ratio	2.97	3.41	4.45
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-73	-35
Operating Cash Flow to CapEx	-11,928.41%	-3,712.24%	-16,216.88%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	5.45	0.00	0.00
Inventory Turnover	1.05	0.68	0.00
Fixed Asset Turnover	0.24	0.05	0.00
Accounts Payable Turnover	0.01	0.00	0.00
Days Sales Outstanding (DSO)	66.92	0.00	0.00
Days Inventory Outstanding (DIO)	346.04	532.90	0.00
Days Payable Outstanding (DPO)	37,372.21	82,865.95	0.00
Cash Conversion Cycle (CCC)	-36,959.25	-82,333.05	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-16	-8.88	-41
Invested Capital Turnover	-0.01	-0.01	0.00
Increase / (Decrease) in Invested Capital	0.00	7.23	-33
Enterprise Value (EV)	419	62	251
Market Capitalization	110	99	301
Book Value per Share	($156.18)	$0.59	$0.07
Tangible Book Value per Share	($156.18)	$0.59	$0.07
Total Capital	17	59	40
Total Debt	55	30	31
Total Long-Term Debt	55	30	31
Net Debt	22	-37	-51
Capital Expenditures (CapEx)	0.36	1.77	0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.06	-15	-12
Debt-free Net Working Capital (DFNWC)	24	52	69
Net Working Capital (NWC)	24	52	69
Net Nonoperating Expense (NNE)	42	3.22	73
Net Nonoperating Obligations (NNO)	22	-37	-51
Total Depreciation and Amortization (D&A)	0.29	0.68	1.13
Debt-free, Cash-free Net Working Capital to Revenue	-7,553.33%	-16,640.86%	0.00%
Debt-free Net Working Capital to Revenue	20,383.33%	55,901.08%	0.00%
Net Working Capital to Revenue	20,383.33%	55,901.08%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.62)	($1.86)
Adjusted Weighted Average Basic Shares Outstanding	0.00	43.54M	75.82M
Adjusted Diluted Earnings per Share	$0.00	($1.62)	($1.86)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	43.54M	75.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	48.92M	158.65M
Normalized Net Operating Profit after Tax (NOPAT)	-36	-65	-68
Normalized NOPAT Margin	-29,654.33%	-70,399.68%	0.00%
Pre Tax Income Margin	-64,242.50%	-73,864.52%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.73%	-4.15%	0.00%

This table displays calculated financial ratios and metrics derived from Fractyl Health's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	0.00	0.00	0.00	47,896,908.00	47,927,214.00	48,098,944.00	48,920,221.00	48,976,636.00	50,289,014.00	137,044,440.00	158,648,963.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	47,896,908.00	47,927,214.00	48,098,944.00	48,920,221.00	48,976,636.00	50,289,014.00	137,044,440.00	158,648,963.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	-0.36	-0.48	-0.52	-0.49	-0.57	-0.91	-0.32	0.06
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	560.00%	-40.28%	-61.11%	-57.14%	-100.00%	-100.00%	-100.00%	0.00%	0.00%
EBITDA Growth	0.00%	0.00%	64.41%	39.24%	-50.49%	-29.93%	-448.39%	-51.23%	-90.20%	-73.10%	137.19%
EBIT Growth	0.00%	0.00%	64.21%	38.77%	-51.00%	-30.82%	-448.37%	-51.12%	-89.76%	-72.68%	135.58%
NOPAT Growth	0.00%	0.00%	-77.93%	-93.56%	-71.51%	-94.21%	-14.93%	-13.46%	4.62%	7.64%	-20.13%
Net Income Growth	0.00%	0.00%	72.16%	43.01%	-47.16%	-30.19%	-614.48%	-61.87%	-96.79%	-75.12%	138.84%
EPS Growth	0.00%	0.00%	97.84%	97.83%	95.01%	94.55%	-188.24%	-58.33%	-47.92%	85.25%	112.24%
Operating Cash Flow Growth	0.00%	0.00%	-22.63%	-60.75%	-63.72%	-60.71%	-114.15%	-13.14%	-25.92%	-25.26%	10.38%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-228.86%	8.75%	338.74%	165.61%	26.38%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%	44.87%	34.29%	-189.67%	-1,143.85%	-367.40%	-99.67%
Revenue Q/Q Growth	-50.00%	-80.56%	371.43%	30.30%	-67.44%	-78.57%	-100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	47.56%	-23.39%	77.73%	-321.62%	-29.87%	-6.53%	5.99%	-16.27%	-63.33%	3.05%	120.20%
EBIT Q/Q Growth	47.43%	-22.98%	77.50%	-320.91%	-29.65%	-6.53%	5.67%	-16.00%	-62.79%	3.05%	119.44%
NOPAT Q/Q Growth	-16.83%	6.43%	-65.95%	-6.70%	-3.52%	-5.95%	1.79%	-5.33%	12.98%	-2.60%	-27.74%
Net Income Q/Q Growth	47.91%	-21.80%	82.68%	-418.63%	-34.50%	-7.75%	4.95%	-17.50%	-63.52%	4.11%	121.08%
EPS Q/Q Growth	42.18%	-16.44%	98.48%	-111.76%	-33.33%	-27.08%	19.67%	-16.33%	-24.56%	87.32%	166.67%
Operating Cash Flow Q/Q Growth	5.47%	3.80%	-10.49%	-59.99%	3.73%	5.57%	-47.23%	15.47%	-7.15%	6.07%	-5.35%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-101.06%	-1.38%	-96.92%	18.07%	44.21%	365.25%	-45.88%	-191.93%
Invested Capital Q/Q Growth	0.00%	0.00%	44.84%	59.12%	-10.85%	-120.57%	34.25%	-80.20%	-375.99%	17.12%	71.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.56%	71.43%	42.42%	44.19%	50.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-44,136.11%	-280,071.43%	-13,233.33%	-42,818.60%	-170,792.86%	-849,100.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-38,536.11%	-185,442.86%	-65,278.79%	-53,453.49%	-169,957.14%	-840,333.33%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-44,369.44%	-280,614.29%	-13,393.94%	-43,265.12%	-172,285.71%	-856,533.33%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-43,741.67%	-274,000.00%	-10,066.67%	-40,067.44%	-165,521.43%	-832,333.33%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	98.59%	97.64%	75.16%	92.61%	96.07%	97.17%	97.92%	99.20%	99.64%	98.55%	106.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	204.31%	-81.35%	-78.41%	-125.00%	1,476.02%	-196.81%	-379.75%	-518.40%	-744.17%	-778.33%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-441.84%	-12.12%	-35.16%	-131.67%	-864.49%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	-431.43%	-9.11%	-32.56%	-126.50%	-840.06%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	0.00%	1,760.15%	-81.35%	-78.41%	-125.00%	47,039.52%	-196.81%	-379.75%	-518.40%	-744.17%	-778.33%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-81.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-9.71	-9.09	-15	-16	-17	-18	-17	-18	-16	-16	-21
NOPAT Margin	-26,975.28%	-129,810.00%	-45,695.15%	-37,417.44%	-118,970.00%	-588,233.33%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.00%	46.67%	25.27%	-3.06%	-23.98%	-93.44%	-12.17%	-28.89%	-58.71%	-62.16%	132.78%
Return On Investment Capital (ROIC_SIMPLE)	-	3.37%	-13.36%	-16.23%	-20.65%	-30.12%	-48.47%	-155.06%	-57.57%	-40.70%	-40.42%
Cost of Revenue to Revenue	69.44%	28.57%	57.58%	55.81%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	12,505.56%	40,285.71%	21,612.12%	14,516.28%	34,264.29%	164,400.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	26,061.11%	145,228.57%	43,709.09%	38,981.40%	135,742.86%	676,033.33%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	38,566.67%	185,514.29%	65,321.21%	53,497.67%	170,007.14%	840,433.33%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-16	-20	-4.42	-19	-24	-26	-24	-28	-46	-44	8.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-20	-4.37	-18	-24	-25	-24	-28	-45	-44	8.91
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.64	2.89	2.41	3.49	9.13	0.00	0.00	31.88	3.40
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.64	2.89	2.41	3.49	9.13	0.00	0.00	31.88	3.40
Price to Revenue (P/Rev)	0.00	916.67	366.67	1,718.65	1,250.06	1,065.42	970.25	4,667.19	26,653.18	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	3,491.32	0.00	1,093.56	689.78	664.32	758.20	5,119.77	11,024.18	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	-1.46	0.34	0.40	0.60	1.06	4.61	-1.65	-9.68	3.23	1.41
Long-Term Debt to Equity	0.00	-1.46	0.34	0.40	0.60	1.06	4.61	-1.65	-9.68	3.23	1.41
Financial Leverage	0.00	-0.57	-1.11	-1.05	-1.08	1.68	-1.16	-1.27	-2.15	-2.33	-1.63
Leverage Ratio	0.00	-2.02	1.94	2.07	2.52	-19.80	2.72	3.97	5.12	6.06	6.57
Compound Leverage Factor	0.00	-1.97	1.46	1.92	2.42	-19.24	2.67	3.94	5.10	5.97	7.03
Debt to Total Capital	0.00%	316.60%	25.42%	28.62%	37.60%	51.48%	82.17%	254.69%	111.52%	76.38%	58.50%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	316.60%	25.42%	28.62%	37.60%	51.48%	82.17%	254.69%	111.52%	76.38%	58.50%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	1,649.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-1,866.03%	74.58%	71.38%	62.40%	48.52%	17.83%	-154.69%	-11.52%	23.62%	41.50%
Debt to EBITDA	0.00	-0.71	-0.41	-0.49	-0.46	-0.42	-0.32	-0.30	-0.25	-0.22	-0.28
Net Debt to EBITDA	0.00	-0.28	1.33	1.28	0.82	0.52	0.14	-0.08	0.38	0.36	0.30
Long-Term Debt to EBITDA	0.00	-0.71	-0.41	-0.49	-0.46	-0.42	-0.32	-0.30	-0.25	-0.22	-0.28
Debt to NOPAT	0.00	-1.55	-0.68	-0.57	-0.53	-0.46	-0.43	-0.43	-0.45	-0.45	-0.46
Net Debt to NOPAT	0.00	-0.61	2.21	1.49	0.95	0.57	0.19	-0.11	0.68	0.75	0.51
Long-Term Debt to NOPAT	0.00	-1.55	-0.68	-0.57	-0.53	-0.46	-0.43	-0.43	-0.45	-0.45	-0.46
Altman Z-Score	0.00	-6.25	-1.86	-1.55	-3.30	-4.84	-7.50	-11.35	-6.55	-5.32	-6.25
Noncontrolling Interest Sharing Ratio	0.00%	-761.50%	0.00%	0.00%	0.00%	-3,086.91%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.19	9.38	7.46	5.58	3.63	2.50	1.22	4.27	4.78	4.28
Quick Ratio	0.00	2.97	9.15	7.17	5.39	3.41	2.24	1.02	4.16	4.45	4.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	-6.20	-12	-13	-25	-20	-11	30	16	-15
Operating Cash Flow to CapEx	-7,444.59%	-7,793.38%	-1,105.85%	-7,206.54%	-8,469.01%	-7,310.73%	-5,597.99%	-21,631.63%	-283,925.00%	-711,200.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	5.45	9.87	5.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	1.05	1.27	1.09	0.71	0.68	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.24	0.08	0.04	0.03	0.05	0.02	0.01	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	66.92	36.99	67.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	346.04	286.51	333.71	512.40	532.90	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	37,372.21	37,991.40	49,009.07	75,786.63	82,865.95	138,282.02	683,123.57	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	-36,959.25	-37,667.90	-48,607.88	-75,274.23	-82,333.05	-138,282.02	-683,123.57	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-16	-8.88	-3.63	-4.03	-8.88	-5.84	-11	-50	-41	-12
Invested Capital Turnover	0.00	-0.01	-0.03	-0.07	-0.05	-0.01	-0.01	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	0.00	-8.88	-3.63	-4.03	7.23	3.05	-6.89	-46	-33	-5.82
Enterprise Value (EV)	0.00	419	-39	130	67	62	45	87	33	251	40
Market Capitalization	110	110	54	205	121	99	58	79	80	301	73
Book Value per Share	$0.00	($156.18)	$2.83	$1.48	$1.05	$0.59	$0.13	($0.37)	($0.06)	$0.07	$0.13
Tangible Book Value per Share	$0.00	($156.18)	$2.83	$1.48	$1.05	$0.59	$0.13	($0.37)	($0.06)	$0.07	$0.13
Total Capital	0.00	17	113	99	81	59	36	12	28	40	52
Total Debt	0.00	55	29	28	30	30	29	30	31	31	30
Total Long-Term Debt	0.00	55	29	28	30	30	29	30	31	31	30
Net Debt	0.00	22	-93	-74	-54	-37	-13	7.69	-47	-51	-33
Capital Expenditures (CapEx)	0.15	0.14	1.06	0.26	0.21	0.23	0.45	0.10	0.01	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-9.06	-11	-10	-13	-15	-14	-17	-17	-12	-13
Debt-free Net Working Capital (DFNWC)	0.00	24	111	92	72	52	28	4.86	61	69	51
Net Working Capital (NWC)	0.00	24	111	92	72	52	28	4.86	61	69	51
Net Nonoperating Expense (NNE)	6.04	10	-12	1.14	6.52	7.32	6.40	9.63	30	27	-30
Net Nonoperating Obligations (NNO)	0.00	22	-93	-74	-54	-37	-12	7.69	-47	-51	-33
Total Depreciation and Amortization (D&A)	0.08	0.04	0.05	0.19	0.21	0.22	0.29	0.27	0.29	0.28	0.28
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-7,553.33%	-7,132.43%	-8,806.72%	-13,123.71%	-16,640.86%	-23,106.67%	-102,558.82%	-554,533.33%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	20,383.33%	75,135.14%	77,541.18%	74,158.76%	55,901.08%	47,073.33%	28,564.71%	2,034,033.33%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	20,383.33%	75,135.14%	77,541.18%	74,158.76%	55,901.08%	47,073.33%	28,564.71%	2,034,033.33%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($11.19)	($0.17)	($0.36)	($0.48)	($0.61)	($0.49)	($0.57)	($0.71)	($0.09)	$0.06
Adjusted Weighted Average Basic Shares Outstanding	0.00	2.08M	29.74M	47.90M	47.97M	43.54M	48.87M	49.04M	64.65M	75.82M	158.49M
Adjusted Diluted Earnings per Share	$0.00	($11.19)	($0.17)	($0.36)	($0.48)	($0.61)	($0.49)	($0.57)	($0.71)	($0.09)	$0.06
Adjusted Weighted Average Diluted Shares Outstanding	0.00	2.08M	29.74M	47.90M	47.97M	43.54M	48.87M	49.04M	64.65M	75.82M	158.49M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	47.90M	47.93M	48.10M	48.92M	48.98M	50.29M	137.04M	158.65M	158.65M
Normalized Net Operating Profit after Tax (NOPAT)	-9.71	-9.09	-15	-16	-17	-18	-17	-18	-16	-16	-15
Normalized NOPAT Margin	-26,975.28%	-129,810.00%	-45,695.15%	-37,417.44%	-118,970.00%	-588,233.33%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-43,741.67%	-274,000.00%	-10,066.67%	-40,067.44%	-165,521.43%	-832,333.33%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.73%	-4.99%	-6.16%	-5.33%	-4.15%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Fractyl Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Fractyl Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Fractyl Health's net income appears to be on an upward trend, with a most recent value of -$140.95 million in 2025, rising from -$77.09 million in 2023. The previous period was -$68.69 million in 2024. Find out what analysts predict for Fractyl Health in the coming months.

Fractyl Health's total operating income in 2025 was -$96.82 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $96.82 million

Over the last 2 years, Fractyl Health's total revenue changed from $120 thousand in 2023 to $0.00 in 2025, a change of -100.0%.

Fractyl Health's total liabilities were at $111.94 million at the end of 2025, a 40.5% increase from 2024, and a 1.8% decrease since 2023.

In the past 2 years, Fractyl Health's cash and equivalents has ranged from $33.21 million in 2023 to $81.54 million in 2025, and is currently $81.54 million as of their latest financial filing in 2025.

Over the last 2 years, Fractyl Health's book value per share changed from -156.18 in 2023 to 0.07 in 2025, a change of -100.0%.

Related Companies

Financial statements for NASDAQ:GUTS last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fractyl Health (GUTS) Financials

Financials Breakdown Chart

Fractyl Health Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fractyl Health (GUTS) Financials

Annual Income Statements for Fractyl Health

Quarterly Income Statements for Fractyl Health

Annual Cash Flow Statements for Fractyl Health

Quarterly Cash Flow Statements for Fractyl Health

Annual Balance Sheets for Fractyl Health

Quarterly Balance Sheets for Fractyl Health

Annual Metrics And Ratios for Fractyl Health

Quarterly Metrics And Ratios for Fractyl Health

Financials Breakdown Chart

Fractyl Health Financials - Frequently Asked Questions

When does Fractyl Health's fiscal year end?

How has Fractyl Health's net income changed over the last 2 years?

What is Fractyl Health's operating income?

How has Fractyl Health's revenue changed over the last 2 years?

How much debt does Fractyl Health have?

How much cash does Fractyl Health have?

How has Fractyl Health's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools